| Literature DB >> 28884126 |
Maria Jasińska-Starczewska1, Iwona Szydłowska2, Bożena Mroczek3, Maria Laszczyńska4, Dariusz Chlubek5, Ewa Kemicer-Chmielewska1, Kornel Chełstowski6, Beata Karakiewicz1, Sylwester Ciećwież2, Andrzej Starczewski2.
Abstract
This study evaluated the effect of menopausal hormone therapy (MHT) on serum concentration of copper in postmenopausal women depending on passive or active exposure to tobacco smoke or lack thereof. The study included healthy postmenopausal women aged 42-69 years, who used (n = 76) or did not use (n = 76) MHT. Salivary cotinine and serum copper concentrations were determined in all the study subjects. Salivary cotinine exceeded 14 ng/ml in 14 women from the MHT group (18.5%) and in 16 controls (21.1%). Up to 41 (27%) study subjects had serum copper above the upper normal limit (1.17 mg/l). No correlation was found between salivary cotinine and serum copper in women with cotinine concentrations <14 ng/ml, and these two parameters correlated weakly in subjects with cotinine >14 ng/ml. Salivary concentration of cotinine increased with serum copper level in the MHT group, but not in the controls; smokers using MHT presented with significantly higher serum copper than nonsmokers. These findings imply that MHT does not affect serum concentration of copper in women who are not exposed to tobacco smoke. However, MHT seems to contribute to unfavorable increase in serum copper in passive and active smokers.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28884126 PMCID: PMC5573097 DOI: 10.1155/2017/5732380
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
General characteristics of the study subjects (n = 152); comparison of MHT users (n = 76) and MHT nonusers (n = 76).
| Parameter | Whole group | MTH users | MTH nonusers |
| ||||
|---|---|---|---|---|---|---|---|---|
|
| SD | Min. | Max. | Med. |
|
| ||
| Age (years) | 55.9 | 5.1 | 42 | 80 | 55 | 55.9 ± 4.5 | 56.0 ± 5.6 | NS |
| BMI (kg/m2) | 26.7 | 4.2 | 19.0 | 43.0 | 25.7 | 26.3 ± 3.9 | 27.1 ± 4.4 | NS |
| Menopause | 50.1 | 4.1 | 39.0 | 65.0 | 50.0 | 49.8 ± 3.9 | 50.3 ± 4.2 | NS |
| Cotinine (ng/ml) | 46.3 | 113.9 | 0.1 | 607.8 | 2.66 | 45.7 ± 119.8 | 46.9 ± 106.4 | NS& |
| Copper (mg/l) | 1.07 | 0.21 | 0.54 | 1.74 | 1.06 | 1.07 ± 0.22 | 1.07 ± 0.21 | NS |
Mean age at menopause; #Student's t-test; &after logarithmic transformation.
Figure 1Correlation between serum concentration of copper and salivary level of cotinine in MHT users and nonusers (Groups I and II). The vertical line represents salivary cotinine level of 14.0 ng/ml; values ≥14.0 ng/ml correspond to active smoking. Thick lines on this and subsequent graphs represent recommended serum concentrations of copper.
Figure 2Correlation between serum concentration of copper and salivary level of cotinine in MHT nonusers exposed to tobacco smoke.
Figure 3Correlation between serum concentration of copper and salivary level of cotinine in MHT users exposed to tobacco smoke.
Figure 4Effects of MHT use (I) or lack thereof (II) and exposure to tobacco smoke (salivary cotinine < 14 ng/ml) or lack thereof (salivary cotinine ≥ 14 ng/ml) on serum concentration of copper; results of ANOVA. p: statistical significance in post hoc Bonferroni test.